Loading…

Targeted‐dose of busulfan: Higher risk of sinusoidal obstructive syndrome observed with systemic exposure dose above 5000 µMol⸱min. A historically controlled clinical trial

Busulfan is given in the conditioning regimens preceding hematopoietic stem cell transplantation (HSCT), and plasma levels can be monitored. A targeted, individualized systemic exposure (SE) dose can be achieved by calculating the area under the plasma concentration versus time curve (AUC). The obje...

Full description

Saved in:
Bibliographic Details
Published in:Hematological oncology 2020-12, Vol.38 (5), p.773-781
Main Authors: Esteves, Iracema, Santos, Fabio Pires Souza, Ribeiro, Andreza Alice Feitosa, Seber, Adriana, Sugawara, Eduardo Kinio, Sobrinho, Jairo José do Nascimento, Barros, José Carlos, Oliveira, José Salvador Rodrigues, Fernandes, Juliana Folloni, Hamerschlak, Nelson, Andersson, Borje S., de Lima, Marcos, Kerbauy, Fabio Rodrigues
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c2649-9b2e3fd85e09dfe6b1dfe12ad1b18ea3b4d1eb6ed935ad192b89cef60e0c2e5d3
cites cdi_FETCH-LOGICAL-c2649-9b2e3fd85e09dfe6b1dfe12ad1b18ea3b4d1eb6ed935ad192b89cef60e0c2e5d3
container_end_page 781
container_issue 5
container_start_page 773
container_title Hematological oncology
container_volume 38
creator Esteves, Iracema
Santos, Fabio Pires Souza
Ribeiro, Andreza Alice Feitosa
Seber, Adriana
Sugawara, Eduardo Kinio
Sobrinho, Jairo José do Nascimento
Barros, José Carlos
Oliveira, José Salvador Rodrigues
Fernandes, Juliana Folloni
Hamerschlak, Nelson
Andersson, Borje S.
de Lima, Marcos
Kerbauy, Fabio Rodrigues
description Busulfan is given in the conditioning regimens preceding hematopoietic stem cell transplantation (HSCT), and plasma levels can be monitored. A targeted, individualized systemic exposure (SE) dose can be achieved by calculating the area under the plasma concentration versus time curve (AUC). The objective of this study was to determine a cutoff value for safety for the AUC for busulfan plasma levels in patients undergoing HSCT. A total of 149 consecutive HSCT patients were studied. After an oral test dose of busulfan, we set target doses of 4000, 5000, or 6000 µMol⸱min/day, and analyzed the AUC of oral or intravenous Bu. These patients were compared with 53 historical control subjects who had received myeloablative conditioning regimen without busulfan pharmacokinetic monitoring. Using a test dose and the administration route had no impact on the sinusoidal obstructive syndrome (SOS) incidence, transplant‐related mortality or 1‐year overall survival. However, patients receiving busulfan at doses set up at AUC > 5000 had an increased risk to develop SOS after HSCT (hazard ratio 3.39, p = 0.034, 95% CI 1.09–10.52). Adjusting the busulfan dose according to SE levels target dose during conditioning is associated with lower rates of oral severe mucositis and SOS. A cutoff of 5000 µMol⸱min is safe and does not impair survival.
doi_str_mv 10.1002/hon.2789
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2473427252</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2473427252</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2649-9b2e3fd85e09dfe6b1dfe12ad1b18ea3b4d1eb6ed935ad192b89cef60e0c2e5d3</originalsourceid><addsrcrecordid>eNp1kbtOHDEUhq0oKGwAiSeILKVJM4vtuZoOoZCNxKUh9ciXM6zBM97YHmC7PEJehSJS6jwKT4KHBbo0tvSdz_-x9CO0T8mcEsIOlm6Ys7rh79CMEs4zSir-Hs1IYhlhOdtGH0O4JiTNSPMBbeesrnldVDP0cCn8FUTQj79-axcAuw7LMYy2E8MhXpirJXjsTbiZBsEMY3BGC4udDNGPKppbwGE9aO96mCD4W9D4zsRlwiFCbxSG-5ULowf8vEBIl96U6TP4358zZx__PvRmmOMjvDQhOm-UsHaNlRuid9amNGXNMFEcvRF2F211wgbYe7l30I-Tr5fHi-z04tv346PTTLGq4BmXDPJONyUQrjuoJE0nZUJTSRsQuSw0BVmB5nmZIGey4Qq6igBRDEqd76DPm9yVdz9HCLG9dqMf0sqWFXVesJqVLFlfNpbyLgQPXbvyphd-3VLSTt20qZt26iapn14CR9mDfhNfy0hCthHujIX1f4PaxcX5c-AToPygVw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2473427252</pqid></control><display><type>article</type><title>Targeted‐dose of busulfan: Higher risk of sinusoidal obstructive syndrome observed with systemic exposure dose above 5000 µMol⸱min. A historically controlled clinical trial</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Esteves, Iracema ; Santos, Fabio Pires Souza ; Ribeiro, Andreza Alice Feitosa ; Seber, Adriana ; Sugawara, Eduardo Kinio ; Sobrinho, Jairo José do Nascimento ; Barros, José Carlos ; Oliveira, José Salvador Rodrigues ; Fernandes, Juliana Folloni ; Hamerschlak, Nelson ; Andersson, Borje S. ; de Lima, Marcos ; Kerbauy, Fabio Rodrigues</creator><creatorcontrib>Esteves, Iracema ; Santos, Fabio Pires Souza ; Ribeiro, Andreza Alice Feitosa ; Seber, Adriana ; Sugawara, Eduardo Kinio ; Sobrinho, Jairo José do Nascimento ; Barros, José Carlos ; Oliveira, José Salvador Rodrigues ; Fernandes, Juliana Folloni ; Hamerschlak, Nelson ; Andersson, Borje S. ; de Lima, Marcos ; Kerbauy, Fabio Rodrigues</creatorcontrib><description>Busulfan is given in the conditioning regimens preceding hematopoietic stem cell transplantation (HSCT), and plasma levels can be monitored. A targeted, individualized systemic exposure (SE) dose can be achieved by calculating the area under the plasma concentration versus time curve (AUC). The objective of this study was to determine a cutoff value for safety for the AUC for busulfan plasma levels in patients undergoing HSCT. A total of 149 consecutive HSCT patients were studied. After an oral test dose of busulfan, we set target doses of 4000, 5000, or 6000 µMol⸱min/day, and analyzed the AUC of oral or intravenous Bu. These patients were compared with 53 historical control subjects who had received myeloablative conditioning regimen without busulfan pharmacokinetic monitoring. Using a test dose and the administration route had no impact on the sinusoidal obstructive syndrome (SOS) incidence, transplant‐related mortality or 1‐year overall survival. However, patients receiving busulfan at doses set up at AUC &gt; 5000 had an increased risk to develop SOS after HSCT (hazard ratio 3.39, p = 0.034, 95% CI 1.09–10.52). Adjusting the busulfan dose according to SE levels target dose during conditioning is associated with lower rates of oral severe mucositis and SOS. A cutoff of 5000 µMol⸱min is safe and does not impair survival.</description><identifier>ISSN: 0278-0232</identifier><identifier>EISSN: 1099-1069</identifier><identifier>DOI: 10.1002/hon.2789</identifier><identifier>PMID: 32779746</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>acute toxicity ; Administration, Intravenous ; Administration, Oral ; Adolescent ; Area Under Curve ; Busulfan ; Busulfan - administration &amp; dosage ; Busulfan - adverse effects ; Busulfan - pharmacokinetics ; Child ; Child, Preschool ; Conditioning ; Controlled Clinical Trials as Topic ; Disease Susceptibility ; Dosage ; Exposure ; Female ; Hematologic Diseases - diagnosis ; Hematologic Diseases - therapy ; Hematopoietic Stem Cell Transplantation - adverse effects ; Hematopoietic stem cells ; hepatic sinusoidal obstructive syndrome ; Hepatic Veno-Occlusive Disease - diagnosis ; Hepatic Veno-Occlusive Disease - epidemiology ; Hepatic Veno-Occlusive Disease - etiology ; Hepatic Veno-Occlusive Disease - mortality ; Humans ; Incidence ; Infant ; Infant, Newborn ; Intravenous administration ; Male ; Mucositis ; Pharmacokinetics ; Plasma levels ; Prognosis ; Stem cell transplantation ; Stem cells ; Survival ; Transplantation ; Transplantation Conditioning - adverse effects ; Transplantation Conditioning - methods ; Transplants &amp; implants ; Young Adult</subject><ispartof>Hematological oncology, 2020-12, Vol.38 (5), p.773-781</ispartof><rights>2020 John Wiley &amp; Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2649-9b2e3fd85e09dfe6b1dfe12ad1b18ea3b4d1eb6ed935ad192b89cef60e0c2e5d3</citedby><cites>FETCH-LOGICAL-c2649-9b2e3fd85e09dfe6b1dfe12ad1b18ea3b4d1eb6ed935ad192b89cef60e0c2e5d3</cites><orcidid>0000-0002-3440-5677</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32779746$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Esteves, Iracema</creatorcontrib><creatorcontrib>Santos, Fabio Pires Souza</creatorcontrib><creatorcontrib>Ribeiro, Andreza Alice Feitosa</creatorcontrib><creatorcontrib>Seber, Adriana</creatorcontrib><creatorcontrib>Sugawara, Eduardo Kinio</creatorcontrib><creatorcontrib>Sobrinho, Jairo José do Nascimento</creatorcontrib><creatorcontrib>Barros, José Carlos</creatorcontrib><creatorcontrib>Oliveira, José Salvador Rodrigues</creatorcontrib><creatorcontrib>Fernandes, Juliana Folloni</creatorcontrib><creatorcontrib>Hamerschlak, Nelson</creatorcontrib><creatorcontrib>Andersson, Borje S.</creatorcontrib><creatorcontrib>de Lima, Marcos</creatorcontrib><creatorcontrib>Kerbauy, Fabio Rodrigues</creatorcontrib><title>Targeted‐dose of busulfan: Higher risk of sinusoidal obstructive syndrome observed with systemic exposure dose above 5000 µMol⸱min. A historically controlled clinical trial</title><title>Hematological oncology</title><addtitle>Hematol Oncol</addtitle><description>Busulfan is given in the conditioning regimens preceding hematopoietic stem cell transplantation (HSCT), and plasma levels can be monitored. A targeted, individualized systemic exposure (SE) dose can be achieved by calculating the area under the plasma concentration versus time curve (AUC). The objective of this study was to determine a cutoff value for safety for the AUC for busulfan plasma levels in patients undergoing HSCT. A total of 149 consecutive HSCT patients were studied. After an oral test dose of busulfan, we set target doses of 4000, 5000, or 6000 µMol⸱min/day, and analyzed the AUC of oral or intravenous Bu. These patients were compared with 53 historical control subjects who had received myeloablative conditioning regimen without busulfan pharmacokinetic monitoring. Using a test dose and the administration route had no impact on the sinusoidal obstructive syndrome (SOS) incidence, transplant‐related mortality or 1‐year overall survival. However, patients receiving busulfan at doses set up at AUC &gt; 5000 had an increased risk to develop SOS after HSCT (hazard ratio 3.39, p = 0.034, 95% CI 1.09–10.52). Adjusting the busulfan dose according to SE levels target dose during conditioning is associated with lower rates of oral severe mucositis and SOS. A cutoff of 5000 µMol⸱min is safe and does not impair survival.</description><subject>acute toxicity</subject><subject>Administration, Intravenous</subject><subject>Administration, Oral</subject><subject>Adolescent</subject><subject>Area Under Curve</subject><subject>Busulfan</subject><subject>Busulfan - administration &amp; dosage</subject><subject>Busulfan - adverse effects</subject><subject>Busulfan - pharmacokinetics</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Conditioning</subject><subject>Controlled Clinical Trials as Topic</subject><subject>Disease Susceptibility</subject><subject>Dosage</subject><subject>Exposure</subject><subject>Female</subject><subject>Hematologic Diseases - diagnosis</subject><subject>Hematologic Diseases - therapy</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Hematopoietic stem cells</subject><subject>hepatic sinusoidal obstructive syndrome</subject><subject>Hepatic Veno-Occlusive Disease - diagnosis</subject><subject>Hepatic Veno-Occlusive Disease - epidemiology</subject><subject>Hepatic Veno-Occlusive Disease - etiology</subject><subject>Hepatic Veno-Occlusive Disease - mortality</subject><subject>Humans</subject><subject>Incidence</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Intravenous administration</subject><subject>Male</subject><subject>Mucositis</subject><subject>Pharmacokinetics</subject><subject>Plasma levels</subject><subject>Prognosis</subject><subject>Stem cell transplantation</subject><subject>Stem cells</subject><subject>Survival</subject><subject>Transplantation</subject><subject>Transplantation Conditioning - adverse effects</subject><subject>Transplantation Conditioning - methods</subject><subject>Transplants &amp; implants</subject><subject>Young Adult</subject><issn>0278-0232</issn><issn>1099-1069</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp1kbtOHDEUhq0oKGwAiSeILKVJM4vtuZoOoZCNxKUh9ciXM6zBM97YHmC7PEJehSJS6jwKT4KHBbo0tvSdz_-x9CO0T8mcEsIOlm6Ys7rh79CMEs4zSir-Hs1IYhlhOdtGH0O4JiTNSPMBbeesrnldVDP0cCn8FUTQj79-axcAuw7LMYy2E8MhXpirJXjsTbiZBsEMY3BGC4udDNGPKppbwGE9aO96mCD4W9D4zsRlwiFCbxSG-5ULowf8vEBIl96U6TP4358zZx__PvRmmOMjvDQhOm-UsHaNlRuid9amNGXNMFEcvRF2F211wgbYe7l30I-Tr5fHi-z04tv346PTTLGq4BmXDPJONyUQrjuoJE0nZUJTSRsQuSw0BVmB5nmZIGey4Qq6igBRDEqd76DPm9yVdz9HCLG9dqMf0sqWFXVesJqVLFlfNpbyLgQPXbvyphd-3VLSTt20qZt26iapn14CR9mDfhNfy0hCthHujIX1f4PaxcX5c-AToPygVw</recordid><startdate>202012</startdate><enddate>202012</enddate><creator>Esteves, Iracema</creator><creator>Santos, Fabio Pires Souza</creator><creator>Ribeiro, Andreza Alice Feitosa</creator><creator>Seber, Adriana</creator><creator>Sugawara, Eduardo Kinio</creator><creator>Sobrinho, Jairo José do Nascimento</creator><creator>Barros, José Carlos</creator><creator>Oliveira, José Salvador Rodrigues</creator><creator>Fernandes, Juliana Folloni</creator><creator>Hamerschlak, Nelson</creator><creator>Andersson, Borje S.</creator><creator>de Lima, Marcos</creator><creator>Kerbauy, Fabio Rodrigues</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7QP</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><orcidid>https://orcid.org/0000-0002-3440-5677</orcidid></search><sort><creationdate>202012</creationdate><title>Targeted‐dose of busulfan: Higher risk of sinusoidal obstructive syndrome observed with systemic exposure dose above 5000 µMol⸱min. A historically controlled clinical trial</title><author>Esteves, Iracema ; Santos, Fabio Pires Souza ; Ribeiro, Andreza Alice Feitosa ; Seber, Adriana ; Sugawara, Eduardo Kinio ; Sobrinho, Jairo José do Nascimento ; Barros, José Carlos ; Oliveira, José Salvador Rodrigues ; Fernandes, Juliana Folloni ; Hamerschlak, Nelson ; Andersson, Borje S. ; de Lima, Marcos ; Kerbauy, Fabio Rodrigues</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2649-9b2e3fd85e09dfe6b1dfe12ad1b18ea3b4d1eb6ed935ad192b89cef60e0c2e5d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>acute toxicity</topic><topic>Administration, Intravenous</topic><topic>Administration, Oral</topic><topic>Adolescent</topic><topic>Area Under Curve</topic><topic>Busulfan</topic><topic>Busulfan - administration &amp; dosage</topic><topic>Busulfan - adverse effects</topic><topic>Busulfan - pharmacokinetics</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Conditioning</topic><topic>Controlled Clinical Trials as Topic</topic><topic>Disease Susceptibility</topic><topic>Dosage</topic><topic>Exposure</topic><topic>Female</topic><topic>Hematologic Diseases - diagnosis</topic><topic>Hematologic Diseases - therapy</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Hematopoietic stem cells</topic><topic>hepatic sinusoidal obstructive syndrome</topic><topic>Hepatic Veno-Occlusive Disease - diagnosis</topic><topic>Hepatic Veno-Occlusive Disease - epidemiology</topic><topic>Hepatic Veno-Occlusive Disease - etiology</topic><topic>Hepatic Veno-Occlusive Disease - mortality</topic><topic>Humans</topic><topic>Incidence</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Intravenous administration</topic><topic>Male</topic><topic>Mucositis</topic><topic>Pharmacokinetics</topic><topic>Plasma levels</topic><topic>Prognosis</topic><topic>Stem cell transplantation</topic><topic>Stem cells</topic><topic>Survival</topic><topic>Transplantation</topic><topic>Transplantation Conditioning - adverse effects</topic><topic>Transplantation Conditioning - methods</topic><topic>Transplants &amp; implants</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Esteves, Iracema</creatorcontrib><creatorcontrib>Santos, Fabio Pires Souza</creatorcontrib><creatorcontrib>Ribeiro, Andreza Alice Feitosa</creatorcontrib><creatorcontrib>Seber, Adriana</creatorcontrib><creatorcontrib>Sugawara, Eduardo Kinio</creatorcontrib><creatorcontrib>Sobrinho, Jairo José do Nascimento</creatorcontrib><creatorcontrib>Barros, José Carlos</creatorcontrib><creatorcontrib>Oliveira, José Salvador Rodrigues</creatorcontrib><creatorcontrib>Fernandes, Juliana Folloni</creatorcontrib><creatorcontrib>Hamerschlak, Nelson</creatorcontrib><creatorcontrib>Andersson, Borje S.</creatorcontrib><creatorcontrib>de Lima, Marcos</creatorcontrib><creatorcontrib>Kerbauy, Fabio Rodrigues</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Hematological oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Esteves, Iracema</au><au>Santos, Fabio Pires Souza</au><au>Ribeiro, Andreza Alice Feitosa</au><au>Seber, Adriana</au><au>Sugawara, Eduardo Kinio</au><au>Sobrinho, Jairo José do Nascimento</au><au>Barros, José Carlos</au><au>Oliveira, José Salvador Rodrigues</au><au>Fernandes, Juliana Folloni</au><au>Hamerschlak, Nelson</au><au>Andersson, Borje S.</au><au>de Lima, Marcos</au><au>Kerbauy, Fabio Rodrigues</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeted‐dose of busulfan: Higher risk of sinusoidal obstructive syndrome observed with systemic exposure dose above 5000 µMol⸱min. A historically controlled clinical trial</atitle><jtitle>Hematological oncology</jtitle><addtitle>Hematol Oncol</addtitle><date>2020-12</date><risdate>2020</risdate><volume>38</volume><issue>5</issue><spage>773</spage><epage>781</epage><pages>773-781</pages><issn>0278-0232</issn><eissn>1099-1069</eissn><abstract>Busulfan is given in the conditioning regimens preceding hematopoietic stem cell transplantation (HSCT), and plasma levels can be monitored. A targeted, individualized systemic exposure (SE) dose can be achieved by calculating the area under the plasma concentration versus time curve (AUC). The objective of this study was to determine a cutoff value for safety for the AUC for busulfan plasma levels in patients undergoing HSCT. A total of 149 consecutive HSCT patients were studied. After an oral test dose of busulfan, we set target doses of 4000, 5000, or 6000 µMol⸱min/day, and analyzed the AUC of oral or intravenous Bu. These patients were compared with 53 historical control subjects who had received myeloablative conditioning regimen without busulfan pharmacokinetic monitoring. Using a test dose and the administration route had no impact on the sinusoidal obstructive syndrome (SOS) incidence, transplant‐related mortality or 1‐year overall survival. However, patients receiving busulfan at doses set up at AUC &gt; 5000 had an increased risk to develop SOS after HSCT (hazard ratio 3.39, p = 0.034, 95% CI 1.09–10.52). Adjusting the busulfan dose according to SE levels target dose during conditioning is associated with lower rates of oral severe mucositis and SOS. A cutoff of 5000 µMol⸱min is safe and does not impair survival.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32779746</pmid><doi>10.1002/hon.2789</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-3440-5677</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0278-0232
ispartof Hematological oncology, 2020-12, Vol.38 (5), p.773-781
issn 0278-0232
1099-1069
language eng
recordid cdi_proquest_journals_2473427252
source Wiley-Blackwell Read & Publish Collection
subjects acute toxicity
Administration, Intravenous
Administration, Oral
Adolescent
Area Under Curve
Busulfan
Busulfan - administration & dosage
Busulfan - adverse effects
Busulfan - pharmacokinetics
Child
Child, Preschool
Conditioning
Controlled Clinical Trials as Topic
Disease Susceptibility
Dosage
Exposure
Female
Hematologic Diseases - diagnosis
Hematologic Diseases - therapy
Hematopoietic Stem Cell Transplantation - adverse effects
Hematopoietic stem cells
hepatic sinusoidal obstructive syndrome
Hepatic Veno-Occlusive Disease - diagnosis
Hepatic Veno-Occlusive Disease - epidemiology
Hepatic Veno-Occlusive Disease - etiology
Hepatic Veno-Occlusive Disease - mortality
Humans
Incidence
Infant
Infant, Newborn
Intravenous administration
Male
Mucositis
Pharmacokinetics
Plasma levels
Prognosis
Stem cell transplantation
Stem cells
Survival
Transplantation
Transplantation Conditioning - adverse effects
Transplantation Conditioning - methods
Transplants & implants
Young Adult
title Targeted‐dose of busulfan: Higher risk of sinusoidal obstructive syndrome observed with systemic exposure dose above 5000 µMol⸱min. A historically controlled clinical trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T22%3A38%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeted%E2%80%90dose%20of%20busulfan:%20Higher%20risk%20of%20sinusoidal%20obstructive%20syndrome%20observed%20with%20systemic%20exposure%20dose%20above%205000%20%C2%B5Mol%E2%B8%B1min.%20A%20historically%20controlled%20clinical%20trial&rft.jtitle=Hematological%20oncology&rft.au=Esteves,%20Iracema&rft.date=2020-12&rft.volume=38&rft.issue=5&rft.spage=773&rft.epage=781&rft.pages=773-781&rft.issn=0278-0232&rft.eissn=1099-1069&rft_id=info:doi/10.1002/hon.2789&rft_dat=%3Cproquest_cross%3E2473427252%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2649-9b2e3fd85e09dfe6b1dfe12ad1b18ea3b4d1eb6ed935ad192b89cef60e0c2e5d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2473427252&rft_id=info:pmid/32779746&rfr_iscdi=true